<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544297</url>
  </required_header>
  <id_info>
    <org_study_id>PEP005-018</org_study_id>
    <nct_id>NCT00544297</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand</brief_title>
  <official_title>A Multi-center, Open-label Study to Examine the Safety and Toleration of 0.05% PEP005 Topical Gel in Patients With Actinic Keratoses on the Dorsum of the Hand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peplin</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Omnicare Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peplin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and toleration of PEP005 Topical Gel,
      administered on an actinic keratosis (AK) treatment area on the top of a hand.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Actinic keratoses (AK) is a common skin condition characterized by rough, scaly patches or
      sores on the top layer of the skin which if left untreated can progress to skin cancer.
      Current treatments can cause scarring and hypopigmentation, be inconvenient, or require long
      treatment duration. Non-invasive alternative therapy for treatment of AK lesions is thus
      being researched.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs); and Local Skin Responses (LSR)</measure>
    <time_frame>57 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The complete clearance rate of AK lesions; partial clearance rate of AK lesions and baseline clearance rate of AK lesions.</measure>
    <time_frame>57 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>PEP005 gel administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.05% PEP005 Topical Gel administered for two consecutive days to a 25cm2 contiguous AK treatment area on the top of the hand</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005 gel</intervention_name>
    <description>Two day application, 0.05%</description>
    <arm_group_label>PEP005 gel administration</arm_group_label>
    <other_name>PEP005</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients at least 18 years of age.

          -  Post-menopausal female patients

          -  4 to 8 clinically typical, visible and discrete AK lesions within an area on the
             dorsum of one hand.

          -  Written informed consent has been obtained.

          -  Agreement from the patient to allow photographs of the selected AK treatment area to
             be taken and used as part of the study data package.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur P Bertolino, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer and VP Medical Affairs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin Surgery Medical Group Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Clinical Research Centre</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078-3250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Clinical Research Centre of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/</url>
    <description>Food and Drug Administration</description>
  </link>
  <link>
    <url>http://www.quorumreview.com</url>
    <description>Human Research Ethics Committee</description>
  </link>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2007</study_first_submitted>
  <study_first_submitted_qc>October 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <disposition_first_submitted>July 13, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>July 13, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 15, 2010</disposition_first_posted>
  <last_update_submitted>March 13, 2015</last_update_submitted>
  <last_update_submitted_qc>March 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <keyword>Topical</keyword>
  <keyword>Dermatology</keyword>
  <keyword>Hand</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

